Alimera Sciences, Inc. (ALIM) Financials
Stock symbol ALIM is outdated, potentially delisted? Maybe it is available on other exchange?
ALIM Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2024 | 150.4 million | 111.6 million |
| March 31, 2024 | 152.5 million | 111.8 million |
| Dec. 31, 2023 | 153.5 million | 107.4 million |
| Sept. 30, 2023 | 154.2 million | 105.4 million |
ALIM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2024 | 915000 | 1.5 million |
| March 31, 2024 | -587000 | 845000 |
| Dec. 31, 2023 | 3.7 million | 805000 |
| Sept. 30, 2023 | -9.8 million | 188000 |
ALIM Net Income
No data available :(
ALIM Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2024 | 10.9 million | 69.7 million | 1.9 million |
| March 31, 2024 | 14.3 million | 69.4 million | 2.0 million |
| Dec. 31, 2023 | 12.1 million | 64.5 million | 2.1 million |
| Sept. 30, 2023 | 8.3 million | 64.2 million | 193000 |
ALIM Shares Outstanding
ALIM Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2024 | 111000 | 4.3 million | 15.9 million | 8.5 million |
| March 31, 2024 | 21000 | 4.4 million | 14.3 million | 9.1 million |
| Dec. 31, 2023 | 85000 | 4.8 million | 13.7 million | 7.8 million |
| Sept. 30, 2023 | 4000 | 4.0 million | 11.5 million | 7.9 million |
ALIM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2024 | 27.0 million | 6.9 million |
| March 31, 2024 | 23.0 million | 6.4 million |
| Dec. 31, 2023 | 26.3 million | 6.7 million |
| Sept. 30, 2023 | 23.4 million | 2.8 million |
ALIM Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ALIM
Price: $5.54
52 week price:
Earnings Per Share: 1.05 USD
P/E Ratio: 5.30
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 7882
Ebitda: -3.1 millionMarket Capitalization: 302.4 million